SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
QHSLab, Inc. (USAQ) trades at a trailing P/E of 30.0, forward P/E of 2.0. Trailing earnings yield is 3.33%, forward earnings yield 50.00%. PEG 0.07 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (60/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.07).
- Forward P/E 2.0 (down from trailing 30.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.07 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.33% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 50.00% as earnings recover.
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — USAQ
Valuation Multiples
P/E (TTM)30.0
Forward P/E2.0
PEG Ratio0.07
Forward PEG0.07
P/B Ratio0.00
P/S Ratio4.31
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.02
Forward EPS (Est.)$0.30
Book Value / Share$0.00
Revenue / Share$0.14
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3.33%
Forward Earnings Yield50.00%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.01 |
$0.00 |
$-23.25K |
- |
| 2017 |
$0.00 |
$0.00 |
$-11.36K |
- |
| 2018 |
$-0.01 |
$0.00 |
$-38.63K |
- |
| 2019 |
$-0.03 |
$0.00 |
$-178.93K |
- |
| 2020 |
$-0.05 |
$124.53K |
$-337.07K |
-270.7% |
| 2021 |
$-0.13 |
$1.41M |
$-1.02M |
-71.9% |
| 2022 |
$-0.16 |
$1.24M |
$-1.43M |
-115.1% |
| 2023 |
$-0.05 |
$1.41M |
$-468.36K |
-33.2% |
| 2024 |
$-0.03 |
$2.13M |
$-259.24K |
-12.2% |
| 2025 |
$0.02 |
$2.69M |
$457.42K |
17% |
